Literature DB >> 12797544

HBcAg-specific CD8 T cells play an important role in virus suppression, and acute flare-up is associated with the expansion of activated memory T cells.

Noriaki Shimada1, Kazuhide Yamamoto, Marcelo J Kuroda, Ryo Terada, Tomomi Hakoda, Hiroyuki Shimomura, Hidenori Hata, Eiichi Nakayama, Yasushi Shiratori.   

Abstract

We analyzed the prevalence and longitudinal fluctuation of hepatitis B virus (HBV)-specific CD8 T cells in chronic HBV infection using an HLA-A2-HBc18-27 tetramer. Thirty-five HLA-A2-positive patients with chronic HBV infection were divided into 17 HBe antigen (HBeAg)-positive and 18 anti-HBe antibody (anti-HBe)-positive patients. Five HLA-A2-positive normal subjects, five HLA-A2-negative patients with chronic HBV infection, and two HLA-A2-positive patients with acute HBV infection were included as controls. HBc18-27-specific CD8 T cells (c18-27-CD8Ts) were detected at a significantly higher prevalence in patients with anti-HBe (6/18) than in those with HBeAg (1/17), and their frequency reached 0.28% of the total CD8 T cells. The prevalence was significantly higher in patients with HBV DNA below 4.0 log genome equivalents (LGE)/ml (5/12) than in those with HBV DNA above 4.0 LGE/ml (2/23). The frequency of c18-27-CD8Ts was consistently higher in liver-infiltrating lymphocytes, ranging from 0.18 to 1.28%, than in autologous peripheral blood lymphocytes. Longitudinal analysis of patients with acute flare-up demonstrated that the elevation of alanine aminotransferase (ALT) was intimately associated with the expansion of c18-27-CD8Ts. Phenotypic analysis revealed that most c18-27-CD8Ts during acute flare-up expressed HLA-DR and CCR5, while those during low-ALT periods showed low expression. Furthermore, most liver-infiltrating c18-27-CD8Ts were positive for HLA-DR and CCR5, suggesting selective recruitment of activated c18-27-CD8Ts into the liver. In conclusion. HBV-specific CD8 T cells play an important role in the suppression of virus replication, and acute flare-up is associated with the expansion and activation of HBV-specific memory cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797544     DOI: 10.1023/a:1023366013858

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.542


  37 in total

Review 1.  Faces and phases of human CD8 T-cell development.

Authors:  D Hamann; M T Roos; R A van Lier
Journal:  Immunol Today       Date:  1999-04

2.  Functional expression of the chemokine receptor CCR5 on virus epitope-specific memory and effector CD8+ T cells.

Authors:  Katsuhiko Fukada; Yuji Sobao; Hiroko Tomiyama; Shinichi Oka; Masafumi Takiguchi
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

3.  Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion.

Authors:  S L Tsai; P J Chen; M Y Lai; P M Yang; J L Sung; J H Huang; L H Hwang; T H Chang; D S Chen
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

Review 4.  Natural type I interferon-producing cells as a link between innate and adaptive immunity.

Authors:  Norimitsu Kadowaki; Yong-Jun Liu
Journal:  Hum Immunol       Date:  2002-12       Impact factor: 2.850

5.  High frequency of circulating HBcAg-specific CD8 T cells in hepatitis B infection: a flow cytometric analysis.

Authors:  S Matsumura; K Yamamoto; N Shimada; N Okano; R Okamoto; T Suzuki; T Hakoda; M Mizuno; T Higashi; T Tsuji
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

6.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

7.  Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy.

Authors:  K Bieganowska; P Höllsberg; G J Buckle; D G Lim; T F Greten; J Schneck; J D Altman; S Jacobson; S L Ledis; B Hanchard; J Chin; O Morgan; P A Roth; D A Hafler
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

Review 8.  Hepatitis B virus immunopathogenesis.

Authors:  F V Chisari; C Ferrari
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

9.  Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen.

Authors:  A Penna; F V Chisari; A Bertoletti; G Missale; P Fowler; T Giuberti; F Fiaccadori; C Ferrari
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  15 in total

1.  Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-06-14       Impact factor: 6.047

2.  Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation.

Authors:  Cheng-Yuan Peng; Chih-Bin Chen; Hsueh-Chou Lai; Wen-Pang Su; Po-Heng Chuang; Hong-Dar Isaac Wu; Long-Bin Jeng
Journal:  Hepatol Int       Date:  2010-12-16       Impact factor: 6.047

3.  Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2.

Authors:  Nina Ank; Klavs Petersen; Lene Malmgaard; Søren C Mogensen; Søren R Paludan
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B.

Authors:  Corinna Jen-Hui Pan; Hui-Lin Wu; Stephanie Fang-Tzu Kuo; Jia-Horng Kao; Tai-Chung Tseng; Chen-Hua Liu; Pei-Jer Chen; Chun-Jen Liu; Ding-Shinn Chen
Journal:  Hepatol Int       Date:  2011-07-16       Impact factor: 6.047

5.  He Jie Tang in the treatment of chronic hepatitis B patients.

Authors:  Ze-Xiong Chen; Shi-Jun Zhang; Shao-Xian Lao; Hong-Tao Hu; Cui-Yi Zhang; Shi-He Guan; Yan-Li Gu
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

6.  High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study.

Authors:  Yoon Jun Kim; Byeong Gwan Kim; Jun-Oh Jung; Jung-Hwan Yoon; Hyo-Suk Lee
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

Review 7.  T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection.

Authors:  Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2012-05-28       Impact factor: 5.742

8.  Downregulation of CCR5 expression on the peripheral blood CD8+ T cells of southeastern Iranian patients with chronic hepatitis B infection.

Authors:  Behzad Nasiri Ahmadabadi; Gholamhossein Hassanshahi; Hossein Khoramdelazad; Vahid Mirzaei; Seyed Mohammad Ali Sajadi; Masomeh Hajghani; Hassan Khodadadi; Reza Pourali; Mohammad Kazemi Arababadi; Derek Kennedy
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

Review 9.  Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure.

Authors:  Andrew Vaillant
Journal:  Viruses       Date:  2021-04-23       Impact factor: 5.048

10.  Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans.

Authors:  Xue-Zhang Duan; Min Wang; Han-Wei Li; Hui Zhuang; Dongping Xu; Fu-Sheng Wang
Journal:  J Clin Immunol       Date:  2004-11       Impact factor: 8.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.